To offer increased flexibility and capacity for production
Lonza, a Swiss supplier to the pharmaceutical industry, is investing in a new manufacturing concept, which will offer increased flexibility and capacity for production that uses continuous flow and microreactor technologies.
The manufacturing concept, which will be established at the firm’s Visp, Switzerland site, aims to help Lonza serve its customers better in the development and manufacture of APIs.
Lonza’s ‘Factory of Tomorrow’ will offer production of multi-tons of intermediates and/or APIs based on continuous flow processing. Lonza currently produces kilograms to several tons of small molecule APIs using microreactors. The new facility will concept will provide an integrated solution where all common unit operations in flow can be streamlined with the Lonza FlowPlate microreactors, enabling faster changeover of processes and efficiencies in production and cleaning. The facility will be ready for full operation in June.
‘We expect to share significant cost savings with our customers as a result of this commitment to novel processing and a long term relationship,’ said Stefan Stoffel, head of Lonza’s chemical manufacturing business unit.